ADMA - ADMAバイオロジックス （ADMA Biologics Inc） ADMAバイオロジックスADMAのチャート
ADMAの企業情報
| symbol | ADMA |
|---|---|
| 会社名 | ADMA Biologics Inc （ADMAバイオロジックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ADMA Biologics Inc. is a late-stage biopharmaceutical company that develops manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers which includes its operations in Georgia; Research and Development which includes its plasma development operations in New Jersey and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate RI-002 is intended for the treatment of primary immune deficiency disease. ADMA バイオロジックスは、米国のバイオ医薬品企業。特定の感染症の治療および予防のためのプラズマベ―スの生物製剤の開発、製造、売買に従事する。同社が焦点を当てる患者集団は、基礎免疫不全障害に苦しむ免疫無防備状態の患者が含まれる。主な製品候補｢RI-002｣は、原発性免疫不全症の治療のために投与される｡ ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. |
| 本社所在地 | 465 State Route 17 Ramsey NJ 07446 USA |
| 代表者氏名 | Steven A. Elms スティーブンA.エルムズ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 201-478-5552 |
| 設立年月日 | 38139 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 295人 |
| url | www.admabiologics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/adma |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -50.10306 |
| 終値（lastsale） | 5.78 |
| 時価総額（marketcap） | 267900190.92 |
| 時価総額 | 時価総額（百万ドル） 275.31610 |
| 売上高 | 売上高（百万ドル） 25.43085 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 263.82142 |
| 当期純利益 | 当期純利益（百万ドル） -60.75549 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ADMA Biologics Inc revenues increased 44% to $8.7M. Net loss increased from $15.6M to $32.6M. Revenues reflect ADMA Bio Manufacturing segment increase from $539K to $3.8M Corporate segment remaining flat at $71K. Higher net loss reflects ADMA Bio Manufacturing segment loss increase from $3.1M to $22.6M Plasma Collection Center segment loss increase of 78% to $2M. |
ADMAのテクニカル分析
ADMAのニュース
ADMA Biologics Inc. (NASDAQ: ADMA) Stock Dropped -9.28% Over A Month – Are There Any Chances Of Growth? 2023/03/04 15:00:00 Marketing Sentinel
During the last session, ADMA Biologics Inc. (NASDAQ:ADMA)’s traded shares were 2.98 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $3.42, reflecting an intraday loss of -1.16% or -$0.04. The 52-week high for the ADMA share is $3.98, that puts it down … ADMA Biologics Inc. (NASDAQ: ADMA) Stock Dropped -9.28% Over A Month – Are There Any Chances Of Growth? Read More »
7 A-Rated Penny Stocks Worth Betting On 2023/02/19 19:05:18 InvestorPlace
It’s super-easy to look for large-cap stocks – those names that seemingly everyone knows, or FAANG stocks that get plenty of attention from both analysts and retail investors. But if you want to stand out from the crowd and find some bargains with some penny stocks , then this one’s for you. Penny stocks don’t necessarily cost a penny – I don’t think I would be that interested in buying them if they only cost a copper coin. But a true penny stock is anything that’s priced at less than $5 per share. That means that you can pick up plenty of shares of any of these names, for not very much money. Of course, there are some caveats. Penny stocks tend to be more volatile than more so-called “established” stocks, so you have to be comfortable with your risk tolerance. Many times penny stocks are either in their early stages, which means they may not be even making a profit yet. Or they could be companies that fell on hard times and are looking to bounce back. If you’re a retail investor you can probably find plenty of advice about volatile penny stocks on social media, which is fine if that’s the game you want to play.
7 A-Rated Healthcare Stocks to Buy for the Future of Medicine 2023/02/12 15:56:18 InvestorPlace
If you’re not investing in healthcare stocks these days, you may be missing out on a huge opportunity. Consider this: We are getting older and living longer as a species. The World Health Organization says that by 2030, 1 in 6 people on Earth will be at least 60 years old. With an aging population comes more medical issues – either ailments that weaken the bodies or medications and treatments to hold off the aging process as long as possible. We’ll be needing and using more drugs as we get older, will rely more on medical professionals and spend more of our incomes on healthcare. That’s why the time is now to capitalize on this trend. My Portfolio Grader tool evaluated healthcare stocks and identified several with “A” grades based on their recent performance, momentum, analyst sentiment and quantitative factors. Snapping up or adding to your positions in these healthcare stocks could be just what the doctor ordered – if you are hoping to get a little richer, that is. LLY Eli Lilly $345.12 ARDX Ardelyx $3.21 GERN Geron $3.01 ACHC Acadia Healthcare $81.30 ADMA ADMA Biologics $3.85 AMS American Shared Hospital Services $3.20 VMD Viemed Healthcare $8.42 Eli Lilly (LLY) Source: Jonathan Weiss / Shutterstock.com Drugmaker Eli Lilly (NYSE: LLY ) is coming off a strong 2022, where it showed gains of 35%.
ADMA Biocenters receives FDA approval for eighth plasma collection center 2023/02/08 14:04:12 Seeking Alpha
ADMA Biologics (ADMA) it had received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond. The facility is now…
ADMA stock gains as guidance exceeds consensus (NASDAQ:ADMA) 2023/01/17 12:28:49 Seeking Alpha
ADMA Biologics (ADMA) added ~3% pre-market Tuesday after pre-announcing its Q4 2022 and full-year financials and setting its 2023 outlook ahead of consensus. Read the full story here.
ADMA Biologics'' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing 2022/03/25 12:34:34 Benzinga
ADMA Biologics Inc (NASDAQ: ADMA ) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022. The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the obligations under the Perceptive Advisors senior secured notes. As previously disclosed, ADMA has engaged Morgan Stanley (NYSE: MS ) as an advisor … Full story available on Benzinga.com
ADMA Biologics gets FDA approval to extend shelf life of Asceniv, Bivigam 2022/03/25 11:28:30 Seeking Alpha
ADMA Biologics (ADMA) said the U.S. Food and Drug Administration ((FDA)) approved to extend the expiration dating to 36 months from 24 months for its Asceniv and Bivigam immune…
ADMA Biologics up in after-hours trading following quarterly top and bottom line beats 2022/03/24 21:06:33 Seeking Alpha
Shares of ADMA Biologics (ADMA) are up 2% in after-hours trading after the company''s Q4 2021 results beat on both the top and bottom lines.
ADMA Biologics GAAP EPS of -$0.09 beats by $0.01, revenue of $26.38M beats by $4.61M 2022/03/24 20:19:11 Seeking Alpha
ADMA Biologics press release (ADMA): Q4 GAAP EPS of -$0.09 beats by $0.01.Revenue of $26.38M (+89.0% Y/Y) beats by $4.61M.Shares +3.3%.
ADMA Biologics Q4 2021 Earnings Preview 2022/03/23 21:35:02 Seeking Alpha
ADMA Biologics (ADMA) is scheduled to announce Q4 earnings results on Thursday, March 24th, after market close.The consensus EPS Estimate is -$0.09 (+55.0% Y/Y) and the consensus…
ADMA Biologics (NASDAQ:ADMA) Coverage Initiated by Analysts at Cantor Fitzgerald 2021/11/09 10:22:41 Dakota Financial News
Cantor Fitzgerald initiated coverage on shares of ADMA Biologics (NASDAQ:ADMA) in a report released on Monday morning, The Fly reports. The firm issued an overweight rating on the biotechnology companys stock. A number of other brokerages also recently weighed in on ADMA. Zacks Investment Research upgraded shares of ADMA Biologics from a hold rating to []
ADMA Biologics (NASDAQ:ADMA) Receives New Coverage from Analysts at Cantor Fitzgerald 2021/11/09 10:22:41 Transcript Daily
Cantor Fitzgerald started coverage on shares of ADMA Biologics (NASDAQ:ADMA) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued an overweight rating on the biotechnology companys stock. Several other equities research analysts have also issued reports on the company. Raymond James reduced their price target on ADMA Biologics []
Analysts Predict A Surge In ADMA Biologics Inc. (NASDAQ: ADMA)? 2021/11/05 11:00:00 Stocks Register
ADMA Biologics Inc. (NASDAQ:ADMA) shares, rose in value on Thursday, 11/04/21, with the stock price down by -5.37% to the previous days close as strong demand from buyers drove the stock to $1.41. Actively observing the price movement in the last trading, the stock closed the session at $1.49, falling within a range of $1.37 Analysts Predict A Surge In ADMA Biologics Inc. (NASDAQ: ADMA)? Read More »
ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021 2021/11/03 11:00:00 Intrado Digital Media
Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET
Why ADMA Biologics Inc. (NASDAQ: ADMA) Stock Should Not Be Taken For Granted By Investors In 2021 2021/11/01 14:30:00 Marketing Sentinel
In the last trading session, 3.14 million shares of the ADMA Biologics Inc. (NASDAQ:ADMA) were traded, and its beta was 1.27. Most recently the companys share price was $1.29, and it changed around -$0.05 or -3.73% from the last close, which brings the market valuation of the company to $177.90M. ADMA currently trades at a Why ADMA Biologics Inc. (NASDAQ: ADMA) Stock Should Not Be Taken For Granted By Investors In 2021 Read More »